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Patients with irritable bowel syndrome (IBS) often associate their symptoms to certain 
foods. In congenital sucrase-isomaltase deficiency (CSID), recessive mutations in the SI 
gene (coding for the disaccharidase digesting sucrose and 60% of dietary starch)1 cause 
clinical features of IBS through colonic accumulation of undigested carbohydrates, 
triggering bowel symptoms.2 Hence, in a previous study,3 we hypothesized that CSID 
variants reducing SI enzymatic activity may contribute to development of IBS symptoms. 
We detected association with increased risk of IBS for 4 rare loss-of-function variants 
typically found in (homozygous) CSID patients, because carriers (heterozygous) of these 
rare variants were more common in patients than in controls.1,4 Through a 2-step 
computational and experimental strategy, the present study aimed to determine whether 
other (dys-)functional SI variants are associated with risk of IBS in addition to known CSID 
mutations. We first aimed to identify all SI rare pathogenic variants (SI-RPVs) on the basis 
of integrated Mendelian Clinically Applicable Pathogenicity (M-CAP) and Combined 
Annotation Dependent Depletion (CADD) predictive (clinically relevant) scores; next, we 
inspected genotype data currently available for 2207 IBS patients from a large ongoing 
project to compare SI-RPV case frequencies with ethnically matched population frequencies 
from the Exome Aggregation Consortium (ExAC).
Methods
Study Subjects
A total of 2207 IBS patients (598 IBS with constipation [IBS-C], 952 IBS with diarrhea 
[IBS-D], 503 IBS with alternating constipation and diarrhea, and 154 unsubtyped IBS 
according to Rome Criteria) of European ancestry were included on the basis of available 
genotype data from the bellygenes initiative study (www.bellygenes.org). On approval from 
local ethical committees, IBS patients were recruited at tertiary centers in Sweden, The 
Netherlands, Belgium, Italy, and United States as described in detail in previous 
publications, including former genetic studies of IBS.5–8 Ethnically matched (non-Finnish, 
European ancestry; N = 33,370) reference population frequency of relevant SI-RVPs were 
extracted from ExAC (http://exac.broadinstitute.org).
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Selection of Sucrase-isomaltase Rare Pathogenic Variants
An inventory of all SI rare variants (minor allele frequency <1%) was created by extracting 
single nucleotide polymorphism data from dbSNP (http://www.ncbi.nlm.nih.gov/snp/). 
Sequential data processing with M-CAP (http://bejerano.stanford.edu/MCAP) and CADD 
(http://cadd.gs.washington.edu/) was then performed to identify and select SI-RPVs. These 
computational resources were used because of their documented power to predict 
deleteriousness (pathogenicity) of DNA substitutions for clinical utility, assigning priority to 
M-CAP scores (pathogenicity cutoff >0.025, 5% misclassification rate) over CADD scores 
(pathogenicity cutoff >0.20, 26% misclassification rate).
Genotype Quality Control and Statistical Analysis
Before extraction of SI-RPV data, stringent quality control filters were applied to available 
IBS patients’ Illumina HumanCoreExome genotype data, including per-sample and per-
marker success rate, relatedness, and removal of population outliers based on principal 
component analysis. To avoid uncertainty, only observed (not imputed) SI-RPV genotypes 
were used, and allele calls were verified by visual inspection of individual cluster plots by 
using Evoker (www.sanger.ac.uk/science/tools/evoker). Population reference genotypes were 
only included for SI-RVPs with data available from >95% ExAC individuals. Association 
testing was performed by using one-tailed χ2 statistics on collapsed SI-RPV data, 
comparing carriers and non-carriers in IBS patients compared with controls from ExAC.
Results
M-CAP/CADD combined analysis of all SI rare variants (N = 2146) resulted in the 
identification of 880 SI-RPVs with high predictive power (5% error rate for most variants). 
High-quality genotypes from IBS patients were available for 46 SI-RPVs, and 17 of these 
with at least 1 IBS carrier and ExAC reference data suitable for comparison were included in 
downstream association analyses (Table 1). We identified 88 IBS carriers (all single SI-RPV 
carriers; 3.99% of the entire cohort), with slightly higher prevalence in IBS-D (4.20%) and 
IBS-C (4.51%) than in other subtypes (Table 1). Compared with the large ethnically 
matched reference population from ExAC, most SI-RPVs occurred at higher frequency in 
IBS patients, and cumulative χ2 tests (carriers of any SI-RPVs vs non-carriers) 
demonstrated significant associations and consistent effects on IBS risk (Table 1). In a 
simulation experiment, 1 million permutations of ExAC data resampled to match case 
sample size resulted >99% of the times in identical findings (SI-RPV carriers more common 
in IBS than in ExAC; P < .001).
Discussion
We provide further evidence linking rare functionally deleterious SI variations to IBS 
susceptibility. Although the large ExAC reference population (chosen to ensure genotype 
representation) does not include data on bowel symptoms, the observed association may 
represent an underestimation of the true genetic risk effects; the global prevalence of IBS is 
near 11%, and a significant proportion of ExAC individuals might thus be affected, with 
potential for inflating the background SI-RPV’s carrier frequency among “controls” 
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compared with an otherwise symptom-free reference group (type II error). The consistent 
observation of higher SI-RPV prevalence in IBS warrants further studies. This has the 
potential to identify groups among IBS patients for individualized management.
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